Revvity Launches EONIS Q System for the Screening and Detection of Newborns with Spinal Muscular Atrophy (SMA) and Severe Combined Immunodeficiency (SCID)
Shots:
- The company has launched a CE-IVD declared platform called Eonis Q System in countries that accept CE marking to allow laboratories to adopt a molecular testing system to detect SMA & SCID in newborns
- EONIS Q is a compact size workflow system that allows the screening & detection of SMA & SCID in ~3hrs., requires no wash steps along with involves a comparatively fewer pipetting & centrifuging steps than conventional wet qPCR solutions
- The EONIS Q system contains the EONIS Q96 instrument and the EONIS SCID-SMA kit along with a dedicated EONIS EASI software
Ref: Business wire | Image: Revvity
Related News:- AstraZeneca and Revvity Enters into Licensing Agreement for Pin-point Editing Technology to Treat Cancer and Immune-mediated Diseases
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
